Literature DB >> 31486489

Long non-coding RNA ROR1-AS1 enhances colorectal cancer metastasis by targeting miR-375.

F-Z Wang1, M-Q Zhang, L Zhang, M-C Zhang.   

Abstract

OBJECTIVE: Recent research has proved that long non-coding RNAs (lncRNAs) play an important role in tumorigenesis. In this research, lncRNA ROR1-AS1 was explored to identify its role in the development of colorectal cancer (CRC). PATIENTS AND METHODS: Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was utilized to measure ROR1-AS1 expression of CRC tissues. Besides, function assays including wound healing assay and transwell assay were conducted to detect the effect of ROR1-AS1 on the metastasis of CRC. Furthermore, Luciferase assays and RNA immunoprecipitation assay (RIP) were used to explore the underlying mechanism.
RESULTS: By comparison with ROR1-AS1 expression in adjacent tissues, the ROR1-AS1 expression level was significantly higher in CRC samples. Moreover, loss of ROR1-AS1 inhibited cell migration and cell invasion of CRC cells. Besides, gain of ROR1-AS1 enhanced cell migration and cell invasion of CRC cells. Furthermore, it was found that ROR1-AS1 acted as a competing endogenous RNA via sponging miR-375 in CRC.
CONCLUSIONS: The present study suggests that ROR1-AS1 could promote cell migration and invasion of CRC by sponging miR-375, which may offer a potential therapeutic target in CRC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31486489     DOI: 10.26355/eurrev_201908_18729

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  Circular RNA circLPAR3 Facilitates Esophageal Squamous Cell Carcinoma Progression Through Upregulating HMGB1 via Sponging miR-375/miR-433.

Authors:  Hongzhong Cheng; Wen Jiang; Zhengji Song; Ting Li; Yulian Li; Libin Zhang; Guoping Wang
Journal:  Onco Targets Ther       Date:  2020-08-04       Impact factor: 4.147

Review 2.  Autophagy and gastrointestinal cancers: the behind the scenes role of long non-coding RNAs in initiation, progression, and treatment resistance.

Authors:  Rana Shafabakhsh; Farzaneh Arianfar; Massoud Vosough; Hamid Reza Mirzaei; Maryam Mahjoubin-Tehran; Hashem Khanbabaei; Hamed Kowsari; Layla Shojaie; Maryam Ebadi Fard Azar; Michael R Hamblin; Hamed Mirzaei
Journal:  Cancer Gene Ther       Date:  2021-01-11       Impact factor: 5.987

3.  Upregulation of long non-coding RNA ROR1-AS1 promotes cell growth and migration in bladder cancer by regulation of miR-504.

Authors:  Qingke Chen; Lingmin Fu
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

4.  LncRNA ROR1‑AS1 high expression and its prognostic significance in liver cancer.

Authors:  Ze Zhang; Shouqian Wang; Fan Yang; Zihui Meng; Yahui Liu
Journal:  Oncol Rep       Date:  2019-11-04       Impact factor: 3.906

5.  LncRNA ROR1-AS1 accelerates osteosarcoma invasion and proliferation through modulating miR-504.

Authors:  Xiangkun Wu; Lihua Yan; Yongxi Liu; Lilin Shang
Journal:  Aging (Albany NY)       Date:  2020-12-19       Impact factor: 5.682

Review 6.  MicroRNA-375: potential cancer suppressor and therapeutic drug.

Authors:  Jiahui Wei; Yiran Lu; Ruiqing Wang; Xiangzhu Xu; Qing Liu; Song He; Huihao Pan; Xinmiao Liu; Bao Yuan; Yu Ding; Jiabao Zhang
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

7.  LncRNAs harbouring regulatory motifs within repeat elements modulate immune response towards COVID-19 disease severity and clinical outcomes.

Authors:  Partha Chattopadhyay; Pallavi Mishra; Kriti Khare; Aanchal Yadav; Priyanka Mehta; Sheeba Saifi; Aparna Swaminathan; Priti Devi; Shaista Parveen; Akansha Tyagi; Vinita Jha; Bansidhar Tarai; Sujeet Jha; Sandeep Budhiraja; Jitendra Narayan; Rajesh Pandey
Journal:  Clin Transl Med       Date:  2022-07

8.  LncRNA LINC00662 promotes colon cancer tumor growth and metastasis by competitively binding with miR-340-5p to regulate CLDN8/IL22 co-expression and activating ERK signaling pathway.

Authors:  Bo Cheng; Aimei Rong; Quanbo Zhou; Wenlu Li
Journal:  J Exp Clin Cancer Res       Date:  2020-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.